ClinicalTrials.gov
public full text
Public Domain
A Study of LM-350 in Subjects With Advanced Solid Tumours
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of LM-24C5 For Advanced Solid Tumors#916439
- HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors#812705
- Study of LM-102 in Subjects in Advanced Tumors#906800
- A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors#885989
- A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors#1073610
Record · ID 1032350
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive